Performance of the FebriDx Rapid Point-of-Care Test for Differentiating Bacterial and Viral Respiratory Tract Infections in Patients with a Suspected Respiratory Tract Infection in the Emergency Department

• Published in: Journal of clinical medicine 2023-12, Vol.13 (1), p.163
• Main Authors: Tong-Minh, Kirby, Daenen, Katrijn, Endeman, Henrik, Ramakers, Christian, Gommers, Diederik, van Gorp, Eric, van der Does, Yuri
• Format: Article
• Language: English
• Subjects: Accuracy; Antibiotics; Bacterial infections; Biomarkers; Blood; Care and treatment; Comorbidity; COVID-19; Diagnosis; Emergency medical care; Emergency service; Hospitals; Immune system; Immunocompetence; Infections; Laboratories; Patients; Physicians; Polymerase chain reaction; Proteins; Respiratory tract diseases; Testing; Tumor necrosis factor-TNF; Viral infections; Vital signs
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13010163

FebriDx is a rapid point-of-care test combining qualitative measurements of C-reactive protein (CRP) and Myxovirus Resistance Protein A (MxA) using a disposable test device to detect and differentiate acute bacterial from viral respiratory tract infections. The goal of this study was to investigate the diagnostic accuracy of FebriDx in patients with suspected respiratory tract infections in the emergency department (ED). This was an observational cohort study, performed in the ED of an academic hospital. Patients were included if they had a suspected infection. The primary outcome was the presence of a bacterial or viral infection, determined by clinical adjudication by an expert panel. The sensitivity, specificity, and positive and negative predictive value of FebriDx for the presence of bacterial versus non-bacterial infections, and viral versus non-viral infections were calculated. Between March 2019 and November 2020, 244 patients were included. A bacterial infection was present in 41%, viral infection was present in 24%, and 4% of the patients had both viral and bacterial pathogens. FebriDx demonstrated high sensitivity in the detection of bacterial infection (87%), high NPV (91%) to rule out bacterial infection, and high specificity (94%) for viral infection in patients with a suspected infection in the ED.